[1] | Stephens JWW.A new malaria parasite of man[J]. Ann Trop Med Parasitol, 1922, 16(4): 383-388. | [2] | Sutherland CJ, Tanomsing N, Nolder D, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally[J]. J Infect Dis, 2010, 201(10): 1544-1550. | [3] | Nakeesathit S, Saralamba N, Pukrittayakamee S, et al. Limited polymorphism of the Kelch propeller domain in Plasmodium malariae and P. ovale isolates from Thailand[J]. Antimicrob Agents Chemother, 2016, 60(7): 4055-4062. | [4] | Mayxay M, Pukrittayakamee S, Newton PN, et al. Mixed-species malaria infections in humans[J]. Trends Parasitol, 2004, 20(5): 233-240. | [5] | Imwong M, Nakeesathit S, Day NP, et al. A review of mixed malaria species infections in anopheline mosquitoes[J]. Malar J, 2011, 10: 253. | [6] | Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia[J]. N Engl J Med, 2008, 359(24): 2619-2620. | [7] | Phyo AP, Nkomo S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study[J]. Lancet, 2012, 379(9830): 1960-1966. | [8] | Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria[J]. N Engl J Med, 2014, 371(5): 411-423. | [9] | Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar[J]. PLoS One, 2013, 8(3): e57689. | [10] | Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria[J]. Nature, 2014, 505(7481): 50-55. | [11] | Ghorbal M, Gorman M, Macpherson CR, et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system[J]. Nat Biotechnol, 2014, 32(8): 819-821. | [12] | Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia[J]. J Infect Dis, 2015, 211(5): 670-679. | [13] | White NJ.Malaria: a molecular marker of artemisinin resistance[J]. Lancet, 2014, 383(9927): 1439-1440. | [14] | Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria[J]. Nature, 2015, 520(7549): 683-687. | [15] | Lu F, Culleton R, Zhang M, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa[J]. N Engl J Med, 2017, 376(10): 991-993. | [16] | Talundzic E, Ndiaye YD, Deme AB, et al. Molecular epidemiology of Plasmodium falciparum kelch13 mutations in senegal determined by using targeted amplicon deep sequencing[J]. Antimicrob Agents Chemother, 2017, 61(3): e02116-16. | [17] | Xu C, Wei Q, Yin K, et al. Surveillance of antimalarial resistance Pfcrt, Pfmdr1, and Pfkelch13 polymorphisms in African Plasmodium falciparum imported to Shandong Province, China[J]. Sci Rep, 2018, 8(1): 12951. | [18] | Li X, Zhang D, Hannink M, et al. Crystal structure of the Kelch domain of human Keap1[J]. J Biol Chem, 2004, 279(52): 54750-54758. | [19] | Bauffe F, Desplans J, Fraisier C, Parzy D.Real-time PCR assay for discrimination of Plasmodium ovale curtisi and Plasmodium ovale wallikeri in the Ivory Coast and in the Comoros Islands[J]. Malar J, 2012, 11: 307. | [20] | Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria[J]. Nature, 2014, 505(7481): 50-55. | [21] | 罗飞, 周爽, 袁熠, 等. 2011-2015年重庆市境外输入性疟疾流行特征分析及防控策略探讨[J].中国血吸虫病防治杂志, 2017, 29(3): 310-314. | [22] | 毛祥华, 邓艳, 董莹,等. 云南省输入性疟疾病例时间分布特征分析[J]. 中国血吸虫病防治杂志, 2017, 29(4): 445-448. | [23] | 张丽, 丰俊, 张少森, 等. 2017年全国消除疟疾进展及疫情特征分析[J].中国寄生虫学与寄生虫病杂志, 2018, 36(3): 201-209. | [24] | Maltha J, Gillet P, Jacobs J.Malaria rapid diagnostic tests in travel medicine[J]. Clin Microbiol Infect, 2013, 19(5): 408-415. | [25] | World Health Organization.Emergency response to artemisinin resistance in the Greater Mekong subregion: Regional FrameWork for Action 2013-2015[R]. Geneva: World Health Organization, 2013. | [26] | World Health Organization.Artemisinin and artemisinin-based combination therapy resistance[R]. Geneva: World Health Organization, 2017. |
|